
David E Kleiner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8828754/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Nonalcoholic fatty liver disease risk and histologic severity are associated with genetic polymorphisms in children. Hepatology, 2023, 77, 197-212.	7.3	8
2	Incidence of Type 2 Diabetes in Children With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2023, 21, 1261-1270.	4.4	5
3	Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus. Clinical Gastroenterology and Hepatology, 2022, 20, 256-268.	4.4	34
4	Performance of Serum-Based Scores for Identification of Mild Hepatic Steatosis in HBV Mono-infected and HBV–HIV Co-infected Adults. Digestive Diseases and Sciences, 2022, 67, 676-688.	2.3	4
5	HepQuant SHUNT Detects Portal Hypertension in Early Stages of Clinically Compensated Chronic Liver Disease. Clinical Gastroenterology and Hepatology, 2022, 20, e890-e894.	4.4	6
6	Nodular regenerative hyperplasia in X-linked agammaglobulinemia: An underestimated and severe complication. Journal of Allergy and Clinical Immunology, 2022, 149, 400-409.e3.	2.9	8
7	Garcinia cambogia, Either Alone or in Combination With Green Tea, Causes Moderate to Severe Liver Injury. Clinical Gastroenterology and Hepatology, 2022, 20, e1416-e1425.	4.4	13
8	The tumour microenvironment shapes innate lymphoid cells in patients with hepatocellular carcinoma. Gut, 2022, 71, 1161-1175.	12.1	60
9	Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. Journal of Hepatology, 2022, 76, 1030-1041.	3.7	74
10	Value of liver biopsy in the diagnosis of drug-induced liver injury. Journal of Hepatology, 2022, 76, 1070-1078.	3.7	21
11	A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma. Oncologist, 2022, 27, e273-e285.	3.7	22
12	Clinical characteristics of antiepileptic-induced liver injury in patients from the DILIN prospective study. Journal of Hepatology, 2022, 76, 832-840.	3.7	16
13	Consensus recommendations for histological criteria of autoimmune hepatitis from the International <scp>AIH</scp> Pathology Group. Liver International, 2022, 42, 1058-1069.	3.9	45
14	Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (<scp>NAFLD</scp>). Alimentary Pharmacology and Therapeutics, 2022, 55, 1441-1451.	3.7	9
15	Changes in serum hepatitis B surface and e antigen, interferonâ€inducible protein 10, and aminotransferase levels during combination therapy of immuneâ€ŧolerant chronic hepatitis B. Hepatology, 2022, 76, 775-787.	7.3	7
16	Prevention and regression of megamitochondria and steatosis by blocking mitochondrial fusion in the liver. IScience, 2022, 25, 103996.	4.1	19
17	Safety of liver biopsy in patients with sickle cell related liver disease: A singleâ€center experience. American Journal of Hematology, 2022, 97, .	4.1	1
18	Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score. Hepatology, 2022, 76, 1150-1163.	7.3	15

#	Article	IF	CITATIONS
19	Nodular Regenerative Hyperplasia of the liver in Juvenile Dermatomyositis. Pediatric Rheumatology, 2022, 20, 30.	2.1	5
20	Validation of the accuracy of the FASTâ,,¢ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms. PLoS ONE, 2022, 17, e0266859.	2.5	20
21	Tip of the iceberg: A comprehensive review of liver disease in Inborn errors of immunity. Hepatology, 2022, 76, 1845-1861.	7.3	4
22	Abnormal liver tests are not sufficient for diagnosis of hepatic graftâ€versusâ€host disease in critically ill patients. Hepatology Communications, 2022, 6, 2210-2220.	4.3	2
23	Letter: nonâ€invasive prediction models to exclude cirrhosis in <scp>NAFLD</scp> —not everyone fits the mould. Authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 56, 182-183.	3.7	0
24	Phenotypic Features of Cystic Lung Disease in Proteus Syndrome: A Clinical Trial. Annals of the American Thoracic Society, 2022, 19, 1871-1880.	3.2	1
25	The Clinical Spectrum and Diagnosis of Oxaliplatin Liver Injury in the Era of Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2021, 19, 2199-2201.	4.4	8
26	Fatty Liver Disease in a Prospective North American Cohort of Adults With Human Immunodeficiency Virus and Hepatitis B Virus Coinfection. Clinical Infectious Diseases, 2021, 73, e3275-e3285.	5.8	15
27	Clinical Predictors of Liver Fibrosis Presence and Progression in Human Immunodeficiency Virus–Associated Nonalcoholic Fatty Liver Disease. Clinical Infectious Diseases, 2021, 72, 2087-2094.	5.8	15
28	APECEDâ€Associated Hepatitis: Clinical, Biochemical, Histological and Treatment Data From a Large, Predominantly American Cohort. Hepatology, 2021, 73, 1088-1104.	7.3	25
29	Tubular Epithelial and Peritubular Capillary Endothelial Injury in COVID-19 AKI. Kidney International Reports, 2021, 6, 518-525.	0.8	10
30	Fifty years of impact on liver pathology: a history of the Gnomes. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 191-200.	2.8	0
31	17â€Beta Hydroxysteroid Dehydrogenase 13 Deficiency Does Not Protect Mice From Obesogenic Diet Injury. Hepatology, 2021, 73, 1701-1716.	7.3	38
32	CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma. Journal of Hepatology, 2021, 74, 1145-1154.	3.7	76
33	Gut Microbiome Directs Hepatocytes to Recruit MDSCs and Promote Cholangiocarcinoma. Cancer Discovery, 2021, 11, 1248-1267.	9.4	117
34	Liver Biopsy Shines a Light on COVID-19-Related Liver Injury. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 881-882.	4.5	5
35	Glycogenosis is common in nonalcoholic fatty liver disease and is independently associated with ballooning, but lower steatosis and lower fibrosis. Liver International, 2021, 41, 996-1011.	3.9	16
36	NAFLD: Reporting Histologic Findings in Clinical Practice. Hepatology, 2021, 73, 2028-2038.	7.3	86

#	Article	IF	CITATIONS
37	Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e520-e533.	3.6	43
38	HLAâ€B*35:01 and Green Tea–Induced Liver Injury. Hepatology, 2021, 73, 2484-2493.	7.3	53
39	Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy. Hepatology, 2021, 73, 2124-2140.	7.3	23
40	Precore and Basal Core Promoter Hepatitis B Virus (HBV) Variants Are Present From a Young Age and Differ Across HBV Genotypes. Hepatology, 2021, 73, 1637-1651.	7.3	11
41	Clinical and Genetic Risk Factors of Recurrent Nonalcoholic Fatty Liver Disease After Liver Transplantation. Clinical and Translational Gastroenterology, 2021, 12, e00302.	2.5	11
42	Imaging, Pathology, and Immune Correlates in the Woodchuck Hepatic Tumor Model. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 71-83.	3.7	4
43	SARS-CoV-2 infection of the oral cavity and saliva. Nature Medicine, 2021, 27, 892-903.	30.7	527
44	Hepatic Steatosis and Steatohepatitis in a Large North American Cohort of Adults With Chronic Hepatitis B. American Journal of Gastroenterology, 2021, 116, 1686-1697.	0.4	20
45	Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease. Clinical Infectious Diseases, 2021, 73, 621-630.	5.8	7
46	Chitinase 3-like 1 is a profibrogenic factor overexpressed in the aging liver and in patients with liver cirrhosis. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	18
47	Highly multiplexed 2-dimensional imaging mass cytometry analysis of HBV-infected liver. JCI Insight, 2021, 6, .	5.0	15
48	Liver disease symptoms are associated with higher risk of adverse clinical outcomes: A longitudinal study of North American adults with chronic Hepatitis B. GastroHep, 2021, 3, 196-208.	0.6	1
49	Platelet count as a screening tool for compensated cirrhosis in chronic viral hepatitis. World Journal of Gastrointestinal Pathophysiology, 2021, 12, 40-50.	1.0	8
50	Durable virological response and functional cure of chronic hepatitis D after longâ€ŧerm peginterferon therapy. Alimentary Pharmacology and Therapeutics, 2021, 54, 176-182.	3.7	16
51	GIMAP5 maintains liver endothelial cell homeostasis and prevents portal hypertension. Journal of Experimental Medicine, 2021, 218, .	8.5	22
52	Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach. Scientific Reports, 2021, 11, 10485.	3.3	6
53	Clinical significance of quantitative e antigen in a cohort of hepatitis B virusâ€infected children and adults in North America. Journal of Viral Hepatitis, 2021, 28, 1042-1056.	2.0	5
54	Allopurinol hepatotoxicity is associated with human leukocyte antigen Class I alleles. Liver International, 2021, 41, 1884-1893.	3.9	17

#	Article	IF	CITATIONS
55	Hepatocellular carcinoma as a complication of Niemannâ€Pick disease type C1. American Journal of Medical Genetics, Part A, 2021, 185, 3111-3117.	1.2	8
56	Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Journal of Hepatology, 2021, 75, 1397-1408.	3.7	133
57	Liver-Resident Bystander CD8+ TÂCells Contribute to Liver Disease Pathogenesis in Chronic Hepatitis D Virus Infection. Gastroenterology, 2021, 161, 1567-1583.e9.	1.3	31
58	Unhealthy Eating, Psychopathology, and Nonalcoholic Fatty Liver Disease in Youth Presenting for Bariatric Surgery. Journal of Pediatric Gastroenterology and Nutrition, 2021, 73, 670-676.	1.8	1
59	A Prospective Study Evaluating Changes in Histology, Clinical and Virologic Outcomes in HBVâ€HIV Coâ€infected Adults in North America. Hepatology, 2021, 74, 1174-1189.	7.3	11
60	Recurrent Nodular Regenerative Hyperplasia Following Liver Transplantation in Common Variable Immunodeficiency. Hepatology, 2021, 74, 1698-1701.	7.3	3
61	Hepatitis B e antigen loss in adults and children with chronic hepatitis B living in North America: A prospective cohort study. Journal of Viral Hepatitis, 2021, 28, 1526-1538.	2.0	6
62	Postbariatric hypoglycemia: symptom patterns and associated risk factors in the Longitudinal Assessment of Bariatric Surgery study. Surgery for Obesity and Related Diseases, 2021, 17, 1787-1798.	1.2	13
63	Risk Factors for Delta Hepatitis in a North American Cohort: Who Should Be Screened?. American Journal of Gastroenterology, 2021, 116, 206-209.	0.4	20
64	Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. New England Journal of Medicine, 2021, 385, 1559-1569.	27.0	406
65	Microbial Translocation in the Context of Hepatitis B Infection and Hepatitis D Infection. Open Forum Infectious Diseases, 2021, 8, ofaa496.	0.9	3
66	Case Report: Fatal Complications of BK Virus-Hemorrhagic Cystitis and Severe Cytokine Release Syndrome Following BK Virus-Specific T-Cells. Frontiers in Immunology, 2021, 12, 801281.	4.8	7
67	Evidence of SARS-CoV-2-Specific T-Cell-Mediated Myocarditis in a MIS-A Case. Frontiers in Immunology, 2021, 12, 779026.	4.8	15
68	Evaluating Noninvasive Markers to Identify Advanced Fibrosis by Liver Biopsy in HBV/HIV Coâ€infected Adults. Hepatology, 2020, 71, 411-421.	7.3	23
69	Exploring the Link Between Platelet Numbers and Vascular Homeostasis Across Early and Late Stages of Fibrosis in Hepatitis C. Digestive Diseases and Sciences, 2020, 65, 524-533.	2.3	4
70	Liver Histology. Clinics in Liver Disease, 2020, 24, 61-74.	2.1	23
71	Complete Pathological Response to Crizotinib in a Patient with ALK-rearranged Lung Adenocarcinoma. Clinical Lung Cancer, 2020, 21, e25-e29.	2.6	1
72	Vibrationâ€controlled transient elastography for the detection of cirrhosis in chronic hepatitis D infection. Journal of Viral Hepatitis, 2020, 27, 428-436.	2.0	27

#	Article	IF	CITATIONS
73	The Delta-4 fibrosis score (D4FS): A novel fibrosis score in chronic hepatitis D. Antiviral Research, 2020, 174, 104691.	4.1	21
74	Vitamin E treatment in NAFLD patients demonstrates that oxidative stress drives steatosis through upregulation of de-novo lipogenesis. Redox Biology, 2020, 37, 101710.	9.0	58
75	Hepatic Histology in Treatmentâ€naÃ⁻ve Children With Chronic Hepatitis B Infection Living in the United States and Canada. Journal of Pediatric Gastroenterology and Nutrition, 2020, 71, 99-105.	1.8	6
76	Role of Hepatitis E Virus Infection in North American Patients With Severe Acute Liver Injury. Clinical and Translational Gastroenterology, 2020, 11, e00273.	2.5	6
77	Progression of Fatty Liver Disease in Children Receiving Standard of Care Lifestyle Advice. Gastroenterology, 2020, 159, 1731-1751.e10.	1.3	49
78	Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: A case series. EClinicalMedicine, 2020, 24, 100434.	7.1	465
79	In Utero Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 769-771.	1.3	10
80	4-HNE Immunohistochemistry and Image Analysis for Detection of Lipid Peroxidation in Human Liver Samples Using Vitamin E Treatment in NAFLD as a Proof of Concept. Journal of Histochemistry and Cytochemistry, 2020, 68, 635-643.	2.5	29
81	Analysis of <scp><i>TP53</i></scp> aflatoxin signature mutation in hepatocellular carcinomas from Guatemala: A crossâ€sectional study (2016â€2017). Health Science Reports, 2020, 3, e155.	1.5	4
82	The first malignant primary hepatic glomus tumor: A case report. International Journal of Surgery Case Reports, 2020, 70, 197-200.	0.6	2
83	State of the Art: Toward Improving Outcomes of Lung and Liver Tumor Biopsies in Clinical Trials—A Multidisciplinary Approach. Journal of Clinical Oncology, 2020, 38, 1633-1640.	1.6	12
84	Cryptosporidium infection in dedicator of cytokinesis 8 (DOCK 8) deficiency. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 3663-3666.e1.	3.8	6
85	Insights into pathogenesis of fatal COVIDâ€19 pneumonia from histopathology with immunohistochemical and viral RNA studies. Histopathology, 2020, 77, 915-925.	2.9	92
86	Letter to the Editor: Quantitative Histological Assessment in Nonalcoholic Fatty Liver Disease. Hepatology, 2020, 72, 785-785.	7.3	0
87	Platelet-derived growth factor receptor-alpha-positive myeloid neoplasm presenting as eosinophilic gastrointestinal disease. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2089-2091.	3.8	3
88	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology, 2020, 158, 1999-2014.e1.	1.3	1,840
89	Intrahepatic cholangiocarcinoma as a rare secondary malignancy after allogeneic hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia: A case report. Pediatric Transplantation, 2020, 24, e13653.	1.0	5
90	Multicenter Validation of Association Between Decline in MRIâ€₽DFF and Histologic Response in NASH. Hepatology, 2020, 72, 1219-1229.	7.3	79

#	Article	IF	CITATIONS
91	Automated quantification and architectural pattern detection of hepatic fibrosis in NAFLD. Annals of Diagnostic Pathology, 2020, 47, 151518.	1.3	37
92	Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2020, 26, 2318-2326.	7.0	54
93	Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight, 2020, 5, .	5.0	13
94	Characterization of Gut Microbiome in Liver Transplant Recipients With Nonalcoholic Steatohepatitis. Transplantation Direct, 2020, 6, e625.	1.6	12
95	Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials. Hepatology, 2019, 70, 522-531.	7.3	106
96	Sclerosing Cholangitis–Like Changes on Magnetic Resonance Cholangiography in Patients With Drug Induced Liver Injury. Clinical Gastroenterology and Hepatology, 2019, 17, 789-790.	4.4	15
97	The Role of Liver Biopsy in Drug-Induced Liver Injury. Current Hepatology Reports, 2019, 18, 287-293.	0.9	1
98	Reply:. Hepatology, 2019, 70, 2241-2242.	7.3	0
99	Portal Pressure in Noncirrhotic Portal Hypertension: To Measure or Not to Measure. Hepatology, 2019, 70, 2228-2230.	7.3	12
100	A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2019, 18, e349-e360.	2.3	31
101	Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV,the, 2019, 6, e821-e830.	4.7	50
102	Standardising the interpretation of liver biopsies in nonâ€alcoholic fatty liver disease clinical trials. Alimentary Pharmacology and Therapeutics, 2019, 50, 1100-1111.	3.7	27
103	Long-Term Changes in Hepatic Fibrosis following Hepatitis C Viral Clearance in Patients with and without HIV. Antiviral Therapy, 2019, 24, 451-457.	1.0	9
104	Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer. Cancer Cell, 2019, 36, 418-430.e6.	16.8	433
105	Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. JAMA Network Open, 2019, 2, e1912565.	5.9	230
106	No evidence of ongoing HIV replication or compartmentalization in tissues during combination antiretroviral therapy: Implications for HIV eradication. Science Advances, 2019, 5, eaav2045.	10.3	60
107	Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease. Gastroenterology, 2019, 157, 1448-1456.e1.	1.3	11
108	The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2019, 68, 599-608.	4.2	97

#	Article	IF	CITATIONS
109	The balance of type 1 and type 2 immune responses in the contexts of hepatitis B infection and hepatitis D infection. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 764-775.	2.8	15
110	Vibration Controlled Transient Elastography (Fibroscan®) in sickle cell liver disease ―could we strike while the liver is hard?. British Journal of Haematology, 2019, 187, 117-123.	2.5	6
111	Bacterial Translocation and Host Immune Activation in Chronic Hepatitis C Infection. Open Forum Infectious Diseases, 2019, 6, .	0.9	13
112	Hepatic Manifestations of Cystic Fibrosis. Clinics in Liver Disease, 2019, 23, 263-277.	2.1	37
113	Lymphocyte-driven regional immunopathology in pneumonitis caused by impaired central immune tolerance. Science Translational Medicine, 2019, 11, .	12.4	52
114	Longitudinal effects of Nucleos(t)ide analogue therapy in chronic hepatitis B patients and the utility of non-invasive fibrosis markers during treatment: A single-center experience for up to 17 years. Antiviral Research, 2019, 168, 61-67.	4.1	3
115	Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum. Hepatology, 2019, 70, 1841-1855.	7.3	64
116	Hepatitis B Surface Antigen Activates Unfolded Protein Response in Forming Ground Glass Hepatocytes of Chronic Hepatitis B. Viruses, 2019, 11, 386.	3.3	35
117	APOBEC Mutagenesis and Copy-Number Alterations Are Drivers of Proteogenomic Tumor Evolution and Heterogeneity in Metastatic Thoracic Tumors. Cell Reports, 2019, 26, 2651-2666.e6.	6.4	92
118	Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage. Clinical Gastroenterology and Hepatology, 2019, 17, 1877-1885.e5.	4.4	145
119	Relationship between resolution of nonâ€alcoholic steatohepatitis and changes in lipoprotein subâ€fractions: a postâ€hoc analysis of the <scp>PIVENS</scp> trial. Alimentary Pharmacology and Therapeutics, 2019, 49, 1205-1213.	3.7	24
120	Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis B. Journal of Viral Hepatitis, 2019, 26, 856-865.	2.0	17
121	Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection. Clinical Gastroenterology and Hepatology, 2019, 17, 2541-2551.e2.	4.4	28
122	Severe and protracted cholestasis in 44 young men taking bodybuilding supplements: assessment of genetic, clinical and chemical risk factors. Alimentary Pharmacology and Therapeutics, 2019, 49, 1195-1204.	3.7	43
123	The Spectrum of Hepatic Involvement in Patients With Telomere Disease. Hepatology, 2019, 69, 2579-2585.	7.3	40
124	Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy. Oncologist, 2019, 24, 1259-1269.	3.7	127
125	A Pilot Genomeâ€Wide Analysis Study Identifies Loci Associated With Response to Obeticholic Acid in Patients With NASH. Hepatology Communications, 2019, 3, 1571-1584.	4.3	16
126	Tandem Orthotopic Living Donor Liver Transplantation Followed by Same Donor Haploidentical Hematopoietic Stem Cell Transplantation for DOCK8 Deficiency. Transplantation, 2019, 103, 2144-2149.	1.0	9

#	Article	IF	CITATIONS
127	Antimicrobials and Antiepileptics Are the Leading Causes of Idiosyncratic Drugâ€induced Liver Injury in American Children. Journal of Pediatric Gastroenterology and Nutrition, 2019, 69, 152-159.	1.8	21
128	Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels. American Journal of Gastroenterology, 2019, 114, 1626-1635.	0.4	65
129	Tremelimumab in Combination With Microwave Ablation in Patients With RefractoryÂBiliary Tract Cancer. Hepatology, 2019, 69, 2048-2060.	7.3	77
130	Spectrum of Liver Disease in Hepatitis B Virus (HBV) Patients Co-infected with Human Immunodeficiency Virus (HIV): Results of the HBV-HIV Cohort Study. American Journal of Gastroenterology, 2019, 114, 746-757.	0.4	33
131	17â€Beta Hydroxysteroid Dehydrogenase 13Âls a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease. Hepatology, 2019, 69, 1504-1519.	7.3	200
132	Expanding the phenotype of COPA syndrome: a kindred with typical and atypical features. Journal of Medical Genetics, 2019, 56, 778-782.	3.2	49
133	Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2019, 17, 156-163.e2.	4.4	322
134	Defective glycosylation and multisystem abnormalities characterize the primary immunodeficiency XMEN disease. Journal of Clinical Investigation, 2019, 130, 507-522.	8.2	74
135	Unanticipated increases in hepatic steatosis among human immunodeficiency virus patients receiving mineralocorticoid receptor antagonist eplerenone for nonâ€alcoholic fatty liver disease. Liver International, 2018, 38, 797-802.	3.9	8
136	Clinically Actionable Hypercholesterolemia and Hypertriglyceridemia in Children with Nonalcoholic Fatty Liver Disease. Journal of Pediatrics, 2018, 198, 76-83.e2.	1.8	24
137	Hepatocellular carcinoma: Liver biopsy in the balance. Hepatology, 2018, 68, 13-15.	7.3	15
138	Mounier-Kuhn Syndrome Mimicking Lymphangioleiomyomatosis. Chest, 2018, 153, e19-e23.	0.8	1
139	The corticosteroid compounds prednisolone and vamorolone do not alter the nociception phenotype and exacerbate liver injury in sickle cell mice. Scientific Reports, 2018, 8, 6081.	3.3	10
140	Relationship Between Metabolic Syndrome, Alanine Aminotransferase Levels, and Liver Disease Severity in a Multiethnic North American Cohort With Chronic Hepatitis B. Diabetes Care, 2018, 41, 1251-1259.	8.6	21
141	Among Patients With Nonalcoholic Fatty Liver Disease, Modest Alcohol Use Is Associated With Less Improvement in Histologic Steatosis and Steatohepatitis. Clinical Gastroenterology and Hepatology, 2018, 16, 1511-1520.e5.	4.4	111
142	Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. Hepatology, 2018, 67, 2001-2012.	7.3	125
143	Diagnostic accuracy of magnetic resonance imaging hepatic proton density fat fraction in pediatric nonalcoholic fatty liver disease. Hepatology, 2018, 67, 858-872.	7.3	112
144	Histopathological challenges in suspected drugâ€induced liver injury. Liver International, 2018, 38, 198-209.	3.9	34

#	Article	IF	CITATIONS
145	Performance characteristics of vibrationâ€controlled transient elastography for evaluation of nonalcoholic fatty liver disease. Hepatology, 2018, 67, 134-144.	7.3	192
146	Bone marrow failure and extramedullary hematopoiesis in McCune-Albright syndrome. Osteoporosis International, 2018, 29, 237-241.	3.1	5
147	Role of humoral immunity against hepatitis B virus core antigen in the pathogenesis of acute liver failure. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E11369-E11378.	7.1	59
148	Microvascular inflammation in renal allograft biopsies assessed by endothelial and leukocyte coâ€immunostain: a retrospective study on reproducibility and clinical/prognostic correlates. Transplant International, 2018, 32, 300-312.	1.6	6
149	Clinical and Histopathologic Features of Interstitial Lung Disease in Erdheim–Chester Disease. Journal of Clinical Medicine, 2018, 7, 243.	2.4	11
150	Drug-Induced Liver Injury: Understanding the Different Immune-Mediated Phenotypes and Clinical Management. Current Hepatology Reports, 2018, 17, 235-244.	0.9	1
151	Deficiency of Adenosine Deaminase 2 in Adult Siblings: Many Years of a Misdiagnosed Disease With Severe Consequences. Frontiers in Immunology, 2018, 9, 1361.	4.8	46
152	Spleen and Liver Volumetrics as Surrogate Markers of Hepatic Venous Pressure Gradient in Patients With Noncirrhotic Portal Hypertension. Hepatology Communications, 2018, 2, 923-932.	4.3	10
153	Drugs and Toxins. , 2018, , 673-779.		13
154	Recent Advances in the Histopathology of Drug-Induced Liver Injury. Surgical Pathology Clinics, 2018, 11, 297-311.	1.7	23
155	The role of HLA-A*33:01 in patients with cholestatic hepatitis attributed to terbinafine. Journal of Hepatology, 2018, 69, 1317-1325.	3.7	32
156	Pulmonary tumor thrombotic microangiopathy and pulmonary veno-occlusive disease in a woman with cervical cancer treated with cediranib and durvalumab. BMC Pulmonary Medicine, 2018, 18, 112.	2.0	8
157	Molecular Signature and Mechanisms of Hepatitis D Virus–Associated Hepatocellular Carcinoma. Molecular Cancer Research, 2018, 16, 1406-1419.	3.4	64
158	Liver Injury Due to Drugs and Herbal Agents. , 2018, , 327-370.		1
159	FGF21 underlies a hormetic response to metabolic stress in methylmalonic acidemia. JCI Insight, 2018, 3,	5.0	50
160	Innumerable Liver Lesions With a More Benign Outcome: A Case Report. American Journal of Gastroenterology, 2018, 113, S1338-S1339.	0.4	0
161	Features of Autoimmune Hepatitis in Patients With Drug-induced Liver Injury. Clinical Gastroenterology and Hepatology, 2017, 15, 103-112.e2.	4.4	144
162	Vemurafenibâ€induced granulomatous hepatitis. Hepatology, 2017, 65, 745-748.	7.3	31

#	Article	IF	CITATIONS
163	A Wolf in Sheep's Clothing in the Era of Non-Invasive Staging: Non-Hodgkin's Lymphoma Masquerading as Serologic HCV Cirrhosis. American Journal of Gastroenterology, 2017, 112, 398-399.	0.4	0
164	Complications of percutaneous liver biopsy with Klatskin needles: a 36â€year singleâ€centre experience. Alimentary Pharmacology and Therapeutics, 2017, 45, 744-753.	3.7	54
165	Associations of gender and a proxy of female menopausal status with histological features of drugâ€induced liver injury. Liver International, 2017, 37, 1723-1730.	3.9	18
166	Challenges in the hepatic histopathology in non-alcoholic fatty liver disease. Gut, 2017, 66, 1539-1540.	12.1	14
167	On beyond staging and grading: Liver biopsy evaluation in a posttreatment world. Hepatology, 2017, 65, 1432-1434.	7.3	8
168	Adultâ€onset cystic fibrosis liver disease: Diagnosis and characterization of an underappreciated entity. Hepatology, 2017, 66, 591-601.	7.3	79
169	Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma. Clinical Cancer Research, 2017, 23, 4633-4641.	7.0	68
170	Effects of Metreleptin in Pediatric Patients With Lipodystrophy. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1511-1519.	3.6	42
171	Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell, 2017, 169, 1327-1341.e23.	28.9	1,794
172	Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis. Gastroenterology, 2017, 153, 753-761.	1.3	209
173	Drug-induced Liver Injury. Gastroenterology Clinics of North America, 2017, 46, 273-296.	2.2	53
174	The role of the hepatopathologist in the assessment of drugâ€induced liver injury. Clinical Liver Disease, 2017, 9, 34-37.	2.1	2
175	Adverse effects of antiretroviral therapy on liver hepatocytes and endothelium in HIV patients: An ultrastructural perspective. Ultrastructural Pathology, 2017, 41, 186-195.	0.9	20
176	High angiopoietin-2 and suppression of tumorigenicity-2 levels correlate with onset of sinusoidal obstructive syndrome—implication for the utility of serial biomarker monitoring. Bone Marrow Transplantation, 2017, 52, 926-928.	2.4	0
177	Low and High Birth Weights Are Risk Factors for Nonalcoholic Fatty Liver Disease in Children. Journal of Pediatrics, 2017, 187, 141-146.e1.	1.8	91
178	Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Reports, 2017, 18, 2780-2794.	6.4	416
179	Determination of hepatitis B phenotype using biochemical andÂserological markers. Journal of Viral Hepatitis, 2017, 24, 320-329.	2.0	55
180	Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements. Hepatology, 2017, 65, 1267-1277.	7.3	105

#	Article	IF	CITATIONS
181	The histopathological evaluation of drugâ€induced liver injury. Histopathology, 2017, 70, 81-93.	2.9	38
182	Gastrointestinal Manifestations of STAT3-Deficient Hyper-IgE Syndrome. Journal of Clinical Immunology, 2017, 37, 695-700.	3.8	52
183	Pattern of Hepatitis B Virus (HBV) Core Antigen (HB CAG +) and Surface Antigen (HBSAG) Staining in Patients Co-Infected with Human Immunodeficiency Virus (HIV). Gastroenterology, 2017, 152, S1070.	1.3	1
184	Spectrum of Liver Disease in Hepatitis B Virus (HBV) Patients Coinfected with Human Immunodeficiency Virus (HIV). Gastroenterology, 2017, 152, S27.	1.3	0
185	Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection. Hepatology Communications, 2017, 1, 288-292.	4.3	10
186	Nonalcoholic fatty liver disease in spinal and bulbar muscular atrophy. Neurology, 2017, 89, 2481-2490.	1.1	27
187	Identification and Characterization of Fenofibrate-Induced Liver Injury. Digestive Diseases and Sciences, 2017, 62, 3596-3604.	2.3	49
188	Human germline hedgehog pathway mutations predispose to fatty liver. Journal of Hepatology, 2017, 67, 809-817.	3.7	24
189	Azathioprine and 6-Mercaptopurine-induced Liver Injury. Journal of Clinical Gastroenterology, 2017, 51, 63-69.	2.2	66
190	Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. Journal of Hepatology, 2017, 66, 545-551.	3.7	624
191	Noninvasive markers for staging fibrosis in chronic delta hepatitis. Alimentary Pharmacology and Therapeutics, 2017, 45, 127-138.	3.7	44
192	Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers. Clinical Cancer Research, 2017, 23, 2267-2276.	7.0	64
193	Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of NonalcoholicÂSteatohepatitis. Clinical Gastroenterology and Hepatology, 2017, 15, 127-131.e2.	4.4	66
194	National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report. Biology of Blood and Marrow Transplantation, 2017, 23, 367-378.	2.0	50
195	Three variants in the nicotinamide adenine dinucleotide phosphate oxidase complex are associated with HCVâ€related liver damage. Hepatology Communications, 2017, 1, 973-982.	4.3	1
196	Magnetic Resonance Elastography Shear Wave Velocity Correlates with Liver Fibrosis and Hepatic Venous Pressure Gradient in Adults with Advanced Liver Disease. BioMed Research International, 2017, 2017, 1-8.	1.9	29
197	Histopathology, grading and staging of nonalcoholic fatty liver disease. Minerva Gastroenterology, 2017, 64, 28-38.	0.5	19
198	Tremelimumab: A monoclonal antibody against CTLA-4—In combination with radiofrequency ablation (RFA) in patients with biliary tract carcinoma (BTC) Journal of Clinical Oncology, 2017, 35, 88-88.	1.6	0

#	Article	IF	CITATIONS
199	Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. JCI Insight, 2016, 1, .	5.0	219
200	Liver injury from nonsteroidal antiâ€inflammatory drugs in the United States. Liver International, 2016, 36, 603-609.	3.9	67
201	Simtuzumab treatment of advanced liver fibrosis in <scp>HIV</scp> and <scp>HCV</scp> â€infected adults: results of a 6â€month openâ€label safety trial. Liver International, 2016, 36, 1783-1792.	3.9	79
202	Analysis of long noncoding RNA expression in hepatocellular carcinoma of different viral etiology. Journal of Translational Medicine, 2016, 14, 328.	4.4	54
203	Reply. Clinical Gastroenterology and Hepatology, 2016, 14, 1845-1846.	4.4	4
204	Plasma Osteopontin Is a Biomarker Specifically Associated with Bronchiolitis Obliterans Syndrome after HCT. Biology of Blood and Marrow Transplantation, 2016, 22, S417-S418.	2.0	3
205	Mo1564 Automated Method to Detect and Quantify Lobular Inflammation and Portal Inflammation in Human Liver Biopsy Images. Gastroenterology, 2016, 150, S1146.	1.3	0
206	Severe Acute Hepatocellular Injury Attributed to OxyELITE Pro: A Case Series. Digestive Diseases and Sciences, 2016, 61, 2741-2748.	2.3	37
207	NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis. Nature, 2016, 531, 253-257.	27.8	552
208	942 Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy (APECED)-Related Hepatitis: Variant of Autoimmune Hepatitis or New Clinical Entity?. Gastroenterology, 2016, 150, S1053.	1.3	0
209	Increased parenchymal damage and steatohepatitis in Caucasian non-alcoholic fatty liver disease patients with common IL1B and IL6 polymorphisms. Alimentary Pharmacology and Therapeutics, 2016, 44, 1253-1264.	3.7	23
210	Ataxia telangiectasia associated with nodular regenerative hyperplasia. Journal of Clinical Immunology, 2016, 36, 739-742.	3.8	6
211	Haploidentical related donor hematopoietic stem cell transplantation withÂpost-transplantation cyclophosphamide for DOCK8 deficiency. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 1239-1242.e1.	3.8	16
212	In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores. Gastroenterology, 2016, 151, 1141-1154.e9.	1.3	100
213	Association between metabolic syndrome and liver histology among NAFLD patients without diabetes. BMJ Open Gastroenterology, 2016, 3, e000114.	2.7	21
214	Tu1725 Deficiency of Adenosine Deaminase 2 (DADA2); A Rare Cause of Hepatoportal Sclerosis and Non-Cirrhotic Portal Hypertension. Gastroenterology, 2016, 150, S1172-S1173.	1.3	0
215	Utilization of HPASubC for the Identification of Sinusoid-Specific Proteins in the Liver. Journal of Proteome Research, 2016, 15, 1623-1629.	3.7	9
216	Hepatobiliary and Pancreatic: Not all that "Glisson's―is fat. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1515-1515.	2.8	0

#	Article	IF	CITATIONS
217	Diminished viral replication and compartmentalization of hepatitis C virus in hepatocellular carcinoma tissue. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 1375-1380.	7.1	50
218	Amoxicillin–Clavulanate-Induced Liver Injury. Digestive Diseases and Sciences, 2016, 61, 2406-2416.	2.3	92
219	Pathology of Alcoholic and Nonalcoholic Fatty Liver Disease. , 2016, , 223-247.		4
220	Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC. Cancer Immunology Research, 2016, 4, 419-430.	3.4	247
221	Hepatitis B Virus–Specific and Global T-Cell Dysfunction in Chronic Hepatitis B. Gastroenterology, 2016, 150, 684-695.e5.	1.3	178
222	Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Metabolism: Clinical and Experimental, 2016, 65, 1080-1086.	3.4	218
223	Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children. Clinics in Liver Disease, 2016, 20, 293-312.	2.1	217
224	Abstract A195: Tremelimimab activates CD4 and CD8+ T cells in patients with hepatocellular carcinoma. , 2016, , .		2
225	A pilot study of AMP-224, a PD-L2 Fc fusion protein, in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic colorectal cancer Journal of Clinical Oncology, 2016, 34, 560-560.	1.6	19
226	A pilot study of immune checkpoint inhibition (tremelimumab and/or MEDI4736) in combination with radiation therapy in patients with unresectable pancreatic cancer Journal of Clinical Oncology, 2016, 34, TPS470-TPS470.	1.6	1
227	Telomere Length and Survival of Patients with Hepatocellular Carcinoma in the United States. PLoS ONE, 2016, 11, e0166828.	2.5	10
228	Abstract 2653: Tremelimimab plus tumor ablation for patients with hepatocellular carcinoma: Clinical results, immunomonitoring analysis of peripheral T cells and tumor biopsies. , 2016, , .		0
229	Abstract 818: Shortened telomere length in hepatocellular carcinoma in the United States. , 2016, , .		0
230	Liver Histology and Clinical Trials for Nonalcoholic Steatohepatitis-Perspectives From 2 Pathologists. Gastroenterology, 2015, 149, 1305-1308.	1.3	51
231	Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell–depleted stem cell transplantation. Blood, 2015, 125, 784-792.	1.4	200
232	Diabetes and prediabetes in patients with hepatitis B residing in North America. Hepatology, 2015, 62, 1364-1374.	7.3	29
233	Transient elastography for the detection of hepatic fibrosis in HIV-monoinfected adults with elevated aminotransferases on antiretroviral therapy. Aids, 2015, 29, 2297-2302.	2.2	42
234	Liver injury is associated with mortality in sickle cell disease. Alimentary Pharmacology and Therapeutics, 2015, 42, 912-921.	3.7	44

#	Article	IF	CITATIONS
235	HIV Through the Looking Glass. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 123-127.	2.1	5
236	High Prevalence of Nonalcoholic Fatty Liver Disease in Adolescents Undergoing Bariatric Surgery. Gastroenterology, 2015, 149, 623-634.e8.	1.3	110
237	Improvement in Liver Histology Is Associated With Reduction in Dyslipidemia in Children With Nonalcoholic Fatty Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2015, 60, 360-367.	1.8	33
238	HDV1 Oâ€04: Molecular characterization of hepatitis D virus associated hepatocellular carcinoma. Journal of Viral Hepatitis, 2015, 22, 2-3.	2.0	0
239	Noncirrhotic portal hypertension: Pathology and nomenclature. Clinical Liver Disease, 2015, 5, 123-126.	2.1	10
240	Pioglitazone for Hepatic Steatosis in HIV/Hepatitis C Virus Coinfection. AIDS Research and Human Retroviruses, 2015, 31, 961-966.	1.1	15
241	A phase II study of TRC105Âin patients with hepatocellular carcinoma who have progressed on sorafenib. United European Gastroenterology Journal, 2015, 3, 453-461.	3.8	36
242	NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. The 2014 Pathology Working Group Report. Biology of Blood and Marrow Transplantation, 2015, 21, 589-603.	2.0	228
243	Systemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver Damage. Cancer Immunology Research, 2015, 3, 557-566.	3.4	44
244	Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet, The, 2015, 385, 1107-1113.	13.7	148
245	Drugâ€induced allergic hepatitis develops in mice when myeloidâ€derived suppressor cells are depleted prior to halothane treatment. Hepatology, 2015, 62, 546-557.	7.3	54
246	Factors associated with the platelet count in patients with chronic hepatitis C. Thrombosis Research, 2015, 135, 823-828.	1.7	21
247	Trials of obeticholic acid for non-alcoholic steatohepatitis – Authors' reply. Lancet, The, 2015, 386, 28-29.	13.7	8
248	LP36 : Understanding hepatitis delta virus and HBsAG kinetics during treatment with prenylation inhibitor lonafarnib via mathematical modeling. Journal of Hepatology, 2015, 62, S281-S282.	3.7	0
249	Under-reporting and Poor Adherence to Monitoring Guidelines for Severe Cases of Isoniazid Hepatotoxicity. Clinical Gastroenterology and Hepatology, 2015, 13, 1676-1682.e1.	4.4	42
250	Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infectious Diseases, The, 2015, 15, 1167-1174.	9.1	216
251	Automatic quantification of lobular inflammation and hepatocyte ballooning in nonalcoholic fatty liver disease liver biopsies. Human Pathology, 2015, 46, 767-775.	2.0	33
252	Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD. Diabetes Care, 2015, 38, 1347-1355.	8.6	162

#	Article	IF	CITATIONS
253	Caspase-8 Deficiency Presenting as Late-Onset Multi-Organ Lymphocytic Infiltration with Granulomas in two Adult Siblings. Journal of Clinical Immunology, 2015, 35, 348-355.	3.8	35
254	Nonalcoholic Steatohepatitis and Hepatic Fibrosis in HIV-1-Monoinfected Adults With Elevated Aminotransferase Levels on Antiretroviral Therapy. Clinical Infectious Diseases, 2015, 60, 1569-78.	5.8	81
255	Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2015, 149, 389-397.e10.	1.3	2,200
256	Virologic Response Following Combined Ledipasvir and Sofosbuvir Administration in Patients With HCV Genotype 1 and HIV Co-infection. JAMA - Journal of the American Medical Association, 2015, 313, 1232.	7.4	186
257	The Significance of Autoantibody Changes Over Time in Primary Biliary Cirrhosis. American Journal of Clinical Pathology, 2015, 144, 601-606.	0.7	30
258	Identification and Characterization of Cefazolin-Induced Liver Injury. Clinical Gastroenterology and Hepatology, 2015, 13, 1328-1336.e2.	4.4	42
259	Comparative analysis of portal hepatic infiltrating leucocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis. Clinical and Experimental Immunology, 2015, 180, 40-51.	2.6	85
260	<scp>NASH</scp> resolution is associated with improvements in <scp>HDL</scp> and triglyceride levels but not improvement in <scp>LDL</scp> or nonâ€ <scp>HDL</scp> â€C levels. Alimentary Pharmacology and Therapeutics, 2015, 41, 301-309.	3.7	48
261	Endemic mycoses in patients with STAT3-mutated hyper-IgE (Job) syndrome. Journal of Allergy and Clinical Immunology, 2015, 136, 1411-1413.e2.	2.9	63
262	Persistent Liver Biochemistry Abnormalities Are More Common in Older Patients and those With Cholestatic Drug Induced Liver Injury. American Journal of Gastroenterology, 2015, 110, 1450-1459.	0.4	85
263	Characteristics of Adults in the Hepatitis B Research Network in North America Reflect Their Country of Origin and Hepatitis B Virus Genotype. Clinical Gastroenterology and Hepatology, 2015, 13, 183-192.	4.4	90
264	Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet, The, 2015, 385, 956-965.	13.7	1,840
265	Clinical and Histologic Features of Azithromycin-Induced Liver Injury. Clinical Gastroenterology and Hepatology, 2015, 13, 369-376.e3.	4.4	95
266	A pilot study of tremelimumab – a monoclonal antibody against CTLA-4 – in combination with either trans catheter arterial chemoembolization (TACE) or radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC) Journal of Clinical Oncology, 2015, 33, 4081-4081.	1.6	15
267	Acute Hepatocellular Injury With Autoimmune Features Associated With Move Free® Dietary Supplement. American Journal of Gastroenterology, 2015, 110, S330.	0.4	1
268	Hepatic Pathology among Patients without Known Liver Disease Undergoing Bariatric Surgery: Observations and a Perspective from the Longitudinal Assessment of Bariatric Surgery (LABS) Study. Seminars in Liver Disease, 2014, 34, 098-107.	3.6	42
269	Bayesian ROC curve estimation under verification bias. Statistics in Medicine, 2014, 33, 5081-5096.	1.6	9
270	Long-term therapy of chronic delta hepatitis with peginterferon alfa. Alimentary Pharmacology and Therapeutics, 2014, 40, 93-104.	3.7	90

#	Article	IF	CITATIONS
271	Liver histology in the diagnosis and prognosis of drug-induced liver injury. Clinical Liver Disease, 2014, 4, 12-16.	2.1	26
272	Long term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease. BMC Gastroenterology, 2014, 14, 166.	2.0	87
273	Hepatic histological findings in suspected drugâ€induced liver injury: Systematic evaluation and clinical associations. Hepatology, 2014, 59, 661-670.	7.3	322
274	Recombinant Human Factor VIIa for Alveolar Hemorrhage Following Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 969-978.	2.0	37
275	Spectrum of statin hepatotoxicity: Experience of the drug-induced liver injury network. Hepatology, 2014, 60, 679-686.	7.3	200
276	Early-Onset Stroke and Vasculopathy Associated with Mutations in ADA2. New England Journal of Medicine, 2014, 370, 911-920.	27.0	687
277	Viral expression and molecular profiling in liver tissue versus microdissected hepatocytes in hepatitis B virus - associated hepatocellular carcinoma. Journal of Translational Medicine, 2014, 12, 230.	4.4	51
278	Immune dysregulation in human subjects with heterozygous germline mutations in <i>CTLA4</i> . Science, 2014, 345, 1623-1627.	12.6	745
279	Histological Abnormalities in Children with Nonalcoholic Fatty Liver Disease and Normal or Mildly Elevated Alanine Aminotransferase Levels. Journal of Pediatrics, 2014, 164, 707-713.e3.	1.8	146
280	The Alcoholic Hepatitis Histologic Score: Structured Prognostic BiopsyÂEvaluation Comes to Alcoholic Hepatitis. Gastroenterology, 2014, 146, 1156-1158.	1.3	10
281	Automatic classification of white regions in liver biopsies by supervised machine learning. Human Pathology, 2014, 45, 785-792.	2.0	69
282	Relationship Between Changes in Serum Levels of Keratin 18 and Changes in Liver Histology in Children and Adults With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2014, 12, 2121-2130.e2.	4.4	97
283	Longitudinal Assessment of High Blood Pressure in Children with Nonalcoholic Fatty Liver Disease. PLoS ONE, 2014, 9, e112569.	2.5	75
284	Nodular Regenerative Hyperplasia in Common Variable Immunodeficiency. Journal of Clinical Immunology, 2013, 33, 748-758.	3.8	112
285	The influence of DNA repair on neurological degeneration, cachexia, skin cancer and internal neoplasms: autopsy report of four xeroderma pigmentosum patients (XP-A, XP-C and XP-D). Acta Neuropathologica Communications, 2013, 1, 4.	5.2	40
286	Presentation and Outcomes with Clinically Apparent Interferon Beta Hepatotoxicity. Digestive Diseases and Sciences, 2013, 58, 1766-1775.	2.3	26
287	Vitamin <scp>E</scp> and changes in serum alanine aminotransferase levels in patients with nonâ€alcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics, 2013, 38, 134-143.	3.7	163
288	Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment Characteristics. JAMA - Journal of the American Medical Association, 2013, 310, 804.	7.4	265

#	Article	IF	CITATIONS
289	Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology, 2013, 58, 1644-1654.	7.3	146
290	Clinical and Histological Features of Idiosyncratic Acute Liver Injury Caused by Temozolomide. Digestive Diseases and Sciences, 2013, 58, 1415-1421.	2.3	25
291	Discordance Among Transient Elastography, Aspartate Aminotransferase to Platelet Ratio Index, and Histologic Assessments of Liver Fibrosis in Patients With Chronic Hepatitis C. Clinical Gastroenterology and Hepatology, 2013, 11, 303-308.e1.	4.4	29
292	The liver diseases of lipodystrophy: The long-term effect of leptin treatment. Journal of Hepatology, 2013, 59, 131-137.	3.7	138
293	Modeling Pathogenesis of Primary Liver Cancer in Lineage-Specific Mouse Cell Types. Gastroenterology, 2013, 145, 221-231.	1.3	153
294	Longâ€ŧerm outcome of chronic hepatitis <scp>C</scp> after sustained virological response to interferonâ€based therapy. Alimentary Pharmacology and Therapeutics, 2013, 37, 887-894.	3.7	44
295	Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: A longitudinal analysis. Hepatology, 2013, 58, 1548-1557.	7.3	96
296	Identification of microRNAs specifically expressed in hepatitis C virusâ€associated hepatocellular carcinoma. International Journal of Cancer, 2013, 133, 816-824.	5.1	70
297	Histopathological Evaluation of Drug-Induced Liver Disease. , 2013, , 241-263.		3
298	Liver Injury From Tumor Necrosis Factor-α Antagonists: Analysis of Thirty-four Cases. Clinical Gastroenterology and Hepatology, 2013, 11, 558-564.e3.	4.4	187
299	Liver stiffness increases acutely during sickle cell vasoâ€occlusive crisis. American Journal of Hematology, 2013, 88, E250-4.	4.1	14
300	Case Series: Biliary Leak After Transjugular Liver Biopsy. American Journal of Gastroenterology, 2013, 108, 145-147.	0.4	6
301	Vanishing bile duct syndrome in human immunodeficiency virus infected adults: A report of two cases. World Journal of Gastroenterology, 2013, 19, 115.	3.3	15
302	Primary Biliary Cirrhosis Overlapping with Autoimmune Hepatitis in an HIV-Infected Patient on Antiretroviral Therapy. Journal of Interdisciplinary Histopathology, 2013, 1, 270.	0.2	6
303	Abstract 2653: Direct oncogenic reprogramming of adult mouse hepatocytes into cancer stem cells , 2013, , .		0
304	Nonalcoholic Fatty Liver Disease: Pathologic Patterns and Biopsy Evaluation in Clinical Research. Seminars in Liver Disease, 2012, 32, 003-013.	3.6	321
305	A 25-Year Study of the Clinical and Histologic Outcomes of Hepatitis C Virus Infection and Its Modes of Transmission in a Cohort of Initially Asymptomatic Blood Donors. Journal of Infectious Diseases, 2012, 206, 654-661.	4.0	28
306	Hydrogen-1 MR Spectroscopy for Measurement and Diagnosis of Hepatic Steatosis. American Journal of Roentgenology, 2012, 199, 2-7.	2.2	46

#	Article	IF	CITATIONS
307	Lung Manifestations in an Autopsy-Based Series of Pulmonary or Disseminated Nontuberculous Mycobacterial Disease. Chest, 2012, 141, 1203-1209.	0.8	43
308	Acute Liver Injury due to Flavocoxid (Limbrel), a Medical Food for Osteoarthritis. Annals of Internal Medicine, 2012, 156, 857.	3.9	47
309	Pathologic Changes in Ipilimumab-Related Hepatitis in Patients with Metastatic Melanoma. Digestive Diseases and Sciences, 2012, 57, 2233-2240.	2.3	131
310	Randomised clinical trial: the benefit of combination therapy with adefovir and lamivudine for chronic hepatitis <scp>B</scp> . Alimentary Pharmacology and Therapeutics, 2012, 35, 1027-1035.	3.7	19
311	Hepatic injury due to drugs, herbal compounds, chemicals and toxins. , 2012, , 645-760.		13
312	Liver Regeneration Signature in Hepatitis B Virus (HBV)-Associated Acute Liver Failure Identified by Gene Expression Profiling. PLoS ONE, 2012, 7, e49611.	2.5	46
313	Inverse relationship of interleukin-6 and mast cells in children with inflammatory and non-inflammatory abdominal pain phenotypes. World Journal of Gastrointestinal Pathophysiology, 2012, 3, 102.	1.0	11
314	CD40 agonist antibody mediated improvement of chronic Cryptosporidium infection in patients with X-linked hyper IgM syndrome. Clinical Immunology, 2012, 143, 152-161.	3.2	20
315	Renal tubular dysfunction during longâ€ŧerm adefovir or tenofovir therapy in chronic hepatitis <scp>B</scp> . Alimentary Pharmacology and Therapeutics, 2012, 35, 1317-1325.	3.7	135
316	Hepatocellular Carcinoma Confirmation, Treatment, and Survival in Surveillance, Epidemiology, and End Results Registries, 1992-2008. Hepatology, 2012, 55, 476-482.	7.3	226
317	Rate of Progression of Hepatic Fibrosis in Patients With Chronic Hepatitis C: Results From the HALT-C Trial. Gastroenterology, 2011, 141, 900-908.e2.	1.3	32
318	Host Response to Translocated Microbial Products Predicts Outcomes of Patients With HBV or HCV Infection. Gastroenterology, 2011, 141, 1220-1230.e3.	1.3	268
319	Markers of Microbial Translocation Are Elevated in Hepatitis B (HBV) and Hepatitis C (HCV) Infection; A Window Into Biology and Surrogate Markers for Detecting Disease Progression. Gastroenterology, 2011, 140, S-897.	1.3	Ο
320	Clinical and Histopathologic Features of Fluoroquinolone-Induced Liver Injury. Clinical Gastroenterology and Hepatology, 2011, 9, 517-523.e3.	4.4	107
321	Acute Hepatitis E Infection Accounts for Some Cases of Suspected Drug-Induced Liver Injury. Gastroenterology, 2011, 141, 1665-1672.e9.	1.3	294
322	GI involvement in disseminated Mycobacterium genavense: endoscopy and histology. Gastrointestinal Endoscopy, 2011, 74, 688-690.	1.0	5
323	Liver Injury Due to Drugs and Herbal Agents. , 2011, , 311-352.		0
324	Update on Fatty Liver Disease and Steatohepatitis. Advances in Anatomic Pathology, 2011, 18, 294-300.	4.3	50

#	Article	IF	CITATIONS
325	Chemokines and Their Receptors in Human Renal Allotransplantation. Transplantation, 2011, 91, 70-77.	1.0	59
326	Characteristics of Idiosyncratic Drugâ€induced Liver Injury in Children. Journal of Pediatric Gastroenterology and Nutrition, 2011, 53, 182-189.	1.8	85
327	Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood, 2011, 117, 4787-4795.	1.4	165
328	Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology, 2011, 53, 448-457.	7.3	261
329	Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology, 2011, 53, 810-820.	7.3	941
330	Reply:. Hepatology, 2011, 53, 2143-2143.	7.3	0
331	Misuse of scoring systems. Hepatology, 2011, 54, 369-370.	7.3	29
332	Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology, 2011, 54, 344-353.	7.3	617
333	The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology, 2011, 54, 931-939.	7.3	279
334	To resect or not to resect? That is the question. Gut, 2011, 60, 1177-1177.	12.1	0
335	Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents. JAMA - Journal of the American Medical Association, 2011, 305, 1659.	7.4	926
336	Abstract 2452: Generation of hepatocellular carcinomas with cancer stem cell properties from primary mouse hepatocytes. , 2011, , .		0
337	Histological classification of liver and intrahepatic bile duct cancers in SEER registries. Journal of Registry Management, 2011, 38, 201-5.	0.1	50
338	Nonalcoholic Steatohepatitis (NASH). , 2010, 15, 65-71.		0
339	Hepatic Gene Networks in Morbidly Obese Patients With Nonalcoholic Fatty Liver Disease. Obesity Surgery, 2010, 20, 1698-1709.	2.1	32
340	The association of mast cells and serotonin in children with chronic abdominal pain of unknown etiology. BMC Research Notes, 2010, 3, 265.	1.4	14
341	Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology, 2010, 51, 121-129.	7.3	1,078
342	Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology, 2010, 51, 201-209.	7.3	245

#	Article	IF	CITATIONS
343	Prognostic value of Ishak fibrosis stage: Findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology, 2010, 51, 585-594.	7.3	155
344	The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology, 2010, 52, 894-903.	7.3	403
345	Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology, 2010, 52, 913-924.	7.3	397
346	Duloxetine hepatotoxicity: a caseâ€series from the drugâ€induced liver injury network. Alimentary Pharmacology and Therapeutics, 2010, 32, 1174-1183.	3.7	63
347	Evaluation of tacrolimus abbreviated areaâ€underâ€theâ€curve monitoring in renal transplant patients who are potientially at risk for adverse events. Clinical Transplantation, 2010, 24, 557-563.	1.6	10
348	Mesothelin as a Potential Therapeutic Target in Human Cholangiocarcinoma. Journal of Cancer, 2010, 1, 141-149.	2.5	50
349	Acute right upper quadrant pain: A lesson in odds. Digestive and Liver Disease, 2010, 42, 72-73.	0.9	0
350	Probabilistic (Bayesian) Modeling of Gene Expression in Transplant Glomerulopathy. Journal of Molecular Diagnostics, 2010, 12, 653-663.	2.8	11
351	Salivary Gland Involvement in Chronic Graft-Versus-Host Disease: Prevalence, Clinical Significance, and Recommendations for Evaluation. Biology of Blood and Marrow Transplantation, 2010, 16, 1362-1369.	2.0	79
352	Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis. New England Journal of Medicine, 2010, 362, 1675-1685.	27.0	2,718
353	A Spectrum of Severe Familial Liver Disorders Associate with Telomerase Mutations. PLoS ONE, 2009, 4, e7926.	2.5	201
354	NASH and cryptogenic cirrhosis: A histological analysis. Annals of Hepatology, 2009, 8, 346-352.	1.5	117
355	Rapid Development of Advanced Liver Fibrosis after Acquisition of Hepatitis C Infection during Primary HIV Infection. AIDS Patient Care and STDs, 2009, 23, 403-406.	2.5	8
356	Compartmental analysis of plasma and liver n-3 essential fatty acids in alcohol-dependent men during withdrawal. Journal of Lipid Research, 2009, 50, 154-161.	4.2	10
357	When the Left Got Left Behind. American Journal of Gastroenterology, 2009, 104, 2644-2645.	0.4	0
358	Host Genetics, Steatosis and Insulin Resistance among African Americans and Caucasian Americans with Hepatitis C Virus Genotype-1 Infection. Intervirology, 2009, 52, 49-56.	2.8	8
359	The Pathology of Drug-Induced Liver Injury. Seminars in Liver Disease, 2009, 29, 364-372.	3.6	107
360	Association of Interleukinâ€15–Induced Peripheral Immune Activation with Hepatic Stellate Cell Activation in Persons Coinfected with Hepatitis C Virus and HIV. Journal of Infectious Diseases, 2009, 200, 619-623.	4.0	23

#	Article	IF	CITATIONS
361	Invasive Aspergillosis Due to <i>Neosartorya udagawae</i> . Clinical Infectious Diseases, 2009, 49, 102-111.	5.8	103
362	MKS3-Related Ciliopathy with Features of Autosomal Recessive Polycystic Kidney Disease, Nephronophthisis, and Joubert Syndrome. Journal of Pediatrics, 2009, 155, 386-392.e1.	1.8	35
363	Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): A histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology, 2009, 49, 809-820.	7.3	335
364	Liver biopsy findings in chronic hepatitis B. Hepatology, 2009, 49, S61-S71.	7.3	104
365	Fibrosis progression in chronic hepatitis C: Morphometric image analysis in the HALT-C trial. Hepatology, 2009, 50, 1738-1749.	7.3	60
366	Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression. Cancer Causes and Control, 2009, 20, 361-368.	1.8	35
367	Clinical trial: pilot study of metformin for the treatment of nonâ€alcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics, 2009, 29, 172-182.	3.7	249
368	Mechanism of action of metformin in nonalcoholic steatohepatitis: authors' reply. Alimentary Pharmacology and Therapeutics, 2009, 29, 603-604.	3.7	1
369	Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemporary Clinical Trials, 2009, 30, 88-96.	1.8	140
370	Reactivation of Hepatitis B With Reappearance of Hepatitis B Surface Antigen After Chemotherapy and Immunosuppression. Clinical Gastroenterology and Hepatology, 2009, 7, 1130-1137.	4.4	62
371	Severe Hepatocellular Injury With Apoptosis Induced by a Hepatitis C Polymerase Inhibitor. Journal of Clinical Gastroenterology, 2009, 43, 374-381.	2.2	25
372	NASH and cryptogenic cirrhosis: a histological analysis. Annals of Hepatology, 2009, 8, 346-52.	1.5	43
373	Monocyte Infiltration and Kidney Allograft Dysfunction During Acute Rejection. American Journal of Transplantation, 2008, 8, 600-607.	4.7	112
374	The Banff 2007 Working Classification of Skin-Containing Composite Tissue Allograft Pathology. American Journal of Transplantation, 2008, 8, 1396-1400.	4.7	397
375	Hepatic Involvement and Portal Hypertension Predict Mortality in Chronic Granulomatous Disease. Gastroenterology, 2008, 134, 1917-1926.	1.3	84
376	Clinical Correlates of Histopathology in Pediatric Nonalcoholic Steatohepatitis. Gastroenterology, 2008, 135, 1961-1971.e2.	1.3	225
377	Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2008, 48, 829-834.	3.7	194
378	Cutaneous sarcoidosis and primary biliary cirrhosis: A chance association or related diseases?. Journal of the American Academy of Dermatology, 2008, 58, 326-335.	1.2	39

#	Article	IF	CITATIONS
379	Placebo in Nonalcoholic Steatohepatitis: Insight Into Natural History and Implications for Future Clinical Trials. Clinical Gastroenterology and Hepatology, 2008, 6, 1243-1248.	4.4	40
380	Fibrosis Progression in African Americans and Caucasian Americans With Chronic Hepatitis C. Clinical Gastroenterology and Hepatology, 2008, 6, 1403-1411.	4.4	37
381	Type 1 Diabetes Associated with Acquired Generalized Lipodystrophy and Insulin Resistance: The Effect of Long-Term Leptin Therapy. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 26-31.	3.6	64
382	Predictors of Acquired Lipodystrophy in Juvenile-Onset Dermatomyositis and a Gradient of Severity. Medicine (United States), 2008, 87, 70-86.	1.0	137
383	Identification of novel markers for liver fibrosis in HIV/hepatitis C virus coinfected individuals using genomics-based approach. Aids, 2008, 22, 1433-1439.	2.2	11
384	Translational Research in Composite Tissue Allotransplantation. , 2008, , 43-54.		0
385	Host-Dependent Patterns of Tissue Injury in Invasive Pulmonary Aspergillosis. American Journal of Clinical Pathology, 2007, 127, 349-355.	0.7	137
386	Pathologic Assessment of Non-alcoholic Fatty Liver Disease. Clinics in Liver Disease, 2007, 11, 17-23.	2.1	61
387	Causes of death in hyper-IgE syndrome. Journal of Allergy and Clinical Immunology, 2007, 119, 1234-1240.	2.9	149
388	Late-onset gastrointestinal pain in juvenile dermatomyositis as a manifestation of ischemic ulceration from chronic endarteropathy. Arthritis and Rheumatism, 2007, 57, 881-884.	6.7	55
389	Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology, 2007, 45, 80-87.	7.3	165
390	Hepatic abnormalities in patients with chronic granulomatous disease. Hepatology, 2007, 45, 675-683.	7.3	102
391	Myxovirus-1 and protein kinase haplotypes and fibrosis in chronic hepatitis C virus. Hepatology, 2007, 46, 74-83.	7.3	11
392	The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology, 2007, 46, 424-429.	7.3	227
393	Clinical Spectrum and Histopathologic Features of Chronic Hepatitis C Infection in Children. Journal of Pediatrics, 2007, 150, 168-174.e1.	1.8	96
394	Hepatoportal venopathy due to disseminated Mycobacterium avium complex infection in a child with IFN-γ receptor 2 deficiency. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 451, 95-100.	2.8	7
395	Cellular and tissue localization of globotriaosylceramide in Fabry disease. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 451, 823-834.	2.8	96
396	Hepatic Histologic Response (HR) to Combination Therapy among HCV/HIV-Coinfected Individuals: Interferon Induces HR Independent of Sustained Virologic Response (SVR). AIDS Research and Human Retroviruses, 2006, 22, 1091-1098.	1.1	5

#	Article	IF	CITATIONS
397	Granulomas in the liver. Seminars in Diagnostic Pathology, 2006, 23, 161-169.	1.5	52
398	Nodular Regenerative Hyperplasia and Severe Portal Hypertension in Cystinosis. Clinical Gastroenterology and Hepatology, 2006, 4, 387-394.	4.4	36
399	Changes in Serum Adipokine Levels During Pioglitazone Treatment for Nonalcoholic Steatohepatitis: Relationship to Histological Improvement. Clinical Gastroenterology and Hepatology, 2006, 4, 1048-1052.	4.4	90
400	Peginterferon and Ribavirin Treatment in African American and Caucasian American Patients With Hepatitis C Genotype 1. Gastroenterology, 2006, 131, 470-477.	1.3	453
401	Histopathologic Diagnosis of Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biology of Blood and Marrow Transplantation, 2006, 12, 31-47.	2.0	427
402	Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis. Experimental Hematology, 2006, 34, 796-801.	0.4	74
403	Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. Hepatology, 2006, 43, 780-787.	7.3	70
404	Nodular regenerative hyperplasia: Not all nodules are created equal. Hepatology, 2006, 44, 7-14.	7.3	222
405	Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection. Hepatology, 2006, 44, 925-935.	7.3	53
406	CT and MRI of Hepatic Abscess in Patients with Chronic Granulomatous Disease. American Journal of Roentgenology, 2006, 187, 482-490.	2.2	39
407	A Novel Case of Bisphosphonate-Related Osteonecrosis of the Torus Palatinus in a Patient with Metastatic Breast Cancer. Oncology, 2006, 71, 306-308.	1.9	21
408	A Novel Bacterium Associated with Lymphadenitis in a Patient with Chronic Granulomatous Disease. PLoS Pathogens, 2006, 2, e28.	4.7	73
409	Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4. Journal of Clinical Oncology, 2006, 24, 2283-2289.	1.6	794
410	Cancers as Wounds that Do Not Heal: Differences and Similarities between Renal Regeneration/Repair and Renal Cell Carcinoma. Cancer Research, 2006, 66, 7216-7224.	0.9	109
411	Sarcoidosis in Chronic Granulomatous Disease. Pediatrics, 2006, 117, e590-e595.	2.1	39
412	Composite Tissue Allotransplantation: Development of a Preclinical Model in Nonhuman Primates. Transplantation, 2005, 80, 1447-1454.	1.0	79
413	Results from a Human Renal Allograft Tolerance Trial Evaluating T-Cell Depletion with Alemtuzumab Combined with Deoxyspergualin. Transplantation, 2005, 80, 1051-1059.	1.0	115
414	Composite Tissue Allotransplantation: Classification of Clinical Acute Skin Rejection. Transplantation, 2005, 80, 1676-1680.	1.0	88

#	Article	IF	CITATIONS
415	Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study. Annals of Surgical Oncology, 2005, 12, 1005-1016.	1.5	477
416	Surgical transplant physical examination: Correlation of renal resistance index and biopsy-proven chronic allograft nephropathy. Journal of the American College of Surgeons, 2005, 200, 552-556.	0.5	11
417	Functionally Significant Renal Allograft Rejection Is Defined by Transcriptional Criteria. American Journal of Transplantation, 2005, 5, 573-581.	4.7	125
418	Molecular Evaluation of BK Polyomavirus Nephropathy. American Journal of Transplantation, 2005, 5, 2883-2893.	4.7	104
419	Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology, 2005, 41, 753-760.	7.3	210
420	Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology, 2005, 41, 1313-1321.	7.3	8,518
421	Malignant insulinoma. Cancer, 2005, 104, 264-272.	4.1	150
422	The Liver Biopsy in Chronic Hepatitis C: A View from the Other Side of the Microscope. Seminars in Liver Disease, 2005, 25, 52-64.	3.6	66
423	Solid organ transplantation at the National Institutes of Health: development of a research-based transplantation practice. Clinical Transplants, 2005, , 131-44.	0.2	1
424	Peripheral CD4+CD8+ T cells are differentiated effector memory cells with antiviral functions. Blood, 2004, 104, 478-486.	1.4	218
425	Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis. British Journal of Haematology, 2004, 124, 777-786.	2.5	73
426	Liver biopsy in patients with inherited disorders of coagulation and chronic hepatitis C. Haemophilia, 2004, 10, 413-421.	2.1	25
427	Donor genomics influence graft events: The effect of donor polymorphisms on acute rejection and chronic allograft nephropathy. Kidney International, 2004, 66, 1686-1693.	5.2	64
428	A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology, 2004, 39, 188-196.	7.3	679
429	Cyclical Cushing Syndrome Presenting in Infancy: An Early Form of Primary Pigmented Nodular Adrenocortical Disease, or a New Entity?. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3173-3182.	3.6	105
430	Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Human Pathology, 2004, 35, 196-199.	2.0	139
431	CORRELATION OF RENAL RESISTANCE INDEX AND BIOPSY PROVEN CHRONIC ALLOGRAFT NEPHROPATHY: A PART OF THE GENERAL TRANSPLANT PHYSICAL EXAM. Transplantation, 2004, 78, 281.	1.0	0
432	Gastrointestinal Involvement in Chronic Granulomatous Disease. Pediatrics, 2004, 114, 462-468.	2.1	427

#	Article	IF	CITATIONS
433	Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology, 2003, 38, 66-74.	7.3	83
434	E1 therapeutic vaccination for chronic hepatitis C: All that glitters is not gold. Hepatology, 2003, 38, 1092-1094.	7.3	1
435	Pilot study of pioglitazone in nonalcoholic steatohepatitis. Gastroenterology, 2003, 124, A708.	1.3	8
436	Progression of fibrosis in chronic hepatitis C. Gastroenterology, 2003, 124, 97-104.	1.3	368
437	Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology, 2003, 124, 352-360.	1.3	124
438	Immunologic monitoring of the transplant recipient: challenges and approaches with antibody induction. Transplantation Reviews, 2003, 17, S20-S25.	2.9	1
439	An unusual presentation of perinatally transmitted hepatitis C. Archives of Disease in Childhood, 2003, 88, 160-161.	1.9	2
440	Analysis of Factors Associated With Outcome in Patients With Malignant Peritoneal Mesothelioma Undergoing Surgical Debulking and Intraperitoneal Chemotherapy. Journal of Clinical Oncology, 2003, 21, 4560-4567.	1.6	321
441	RESULTS FROM A HUMAN RENAL ALLOGRAFT TOLERANCE TRIAL EVALUATING THE HUMANIZED CD52-SPECIFIC MONOCLONAL ANTIBODY ALEMTUZUMAB (CAMPATH-1H). Transplantation, 2003, 76, 120-129.	1.0	413
442	BK virus and SV40 co-infection in polyomavirus nehropathy1. Transplantation, 2002, 74, 1497-1504.	1.0	110
443	Hepatic Abscess in Patients With Chronic Granulomatous Disease. Annals of Surgery, 2002, 235, 383-391.	4.2	119
444	Molecular and immunohistochemical characterization of the onset and resolution of human renal allograft ischemia-reperfusion injury. Transplantation, 2002, 74, 916-923.	1.0	95
445	Antitumor Effects in Mice of the Intravenous Injection of Attenuated Salmonella Typhimurium. Journal of Immunotherapy, 2002, 25, 218-225.	2.4	67
446	Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. Lancet, The, 2002, 360, 1662-1664.	13.7	116
447	Risk factors for positive minor salivary gland biopsy findings in Sjögren's syndrome and dry mouth patients. Arthritis and Rheumatism, 2002, 47, 189-195.	6.7	22
448	Prevalence and clinical significance of lymphocytic foci in minor salivary glands of healthy volunteers. Arthritis and Rheumatism, 2002, 47, 520-524.	6.7	83
449	A new cause of Zollinger–Ellison syndrome: Non–Small cell lung cancer. Gastroenterology, 2001, 120, 1271-1278.	1.3	25
450	Dysfunctional LAD-1 neutrophils and colitis. Gastroenterology, 2001, 121, 958-964.	1.3	62

#	Article	IF	CITATIONS
451	Phase I Clinical Trial of Alitretinoin and Tamoxifen in Breast Cancer Patients: Toxicity, Pharmacokinetic, and Biomarker Evaluations. Journal of Clinical Oncology, 2001, 19, 2754-2763.	1.6	44
452	Stability of HCV-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers. Journal of Viral Hepatitis, 2001, 8, 256-263.	2.0	42
453	6 Pathology of hepatitis C. Biomedical Research Reports, 2000, , 107-III.	0.3	0
454	Validation of a model of colon cancer progression. Journal of Pathology, 2000, 192, 446-454.	4.5	208
455	Long-Term Therapy of Chronic Hepatitis B With Lamivudine. Hepatology, 2000, 32, 828-834.	7.3	326
456	Efficacy and Safety of Troglitazone in the Treatment of Lipodystrophy Syndromes. Annals of Internal Medicine, 2000, 133, 263.	3.9	265
457	Loss of heterozygosity in P53, BRCA1, and estrogen receptor genes and correlation to expression of p53 protein in ovarian epithelial tumors of different cell types and biological behavior. Human Pathology, 2000, 31, 233-238.	2.0	24
458	Active synovial matrix metalloproteinase-2 is associated with radiographic erosions in patients with early synovitis. Arthritis Research and Therapy, 2000, 2, 145-53.	3.5	67
459	Application of NIDDK nash pathologic protocol to patients with non-alcoholic fatty liver disease. Gastroenterology, 2000, 118, A974.	1.3	5
460	Biophysical and Functional Characterization of Full-length, Recombinant Human Tissue Inhibitor of Metalloproteinases-2 (TIMP-2) Produced in Escherichia coli. Journal of Biological Chemistry, 1999, 274, 21362-21368.	3.4	99
461	Matrix metalloproteinases and metastasis. Cancer Chemotherapy and Pharmacology, 1999, 43, S42-S51.	2.3	621
462	Lamivudine for chronic delta hepatitis. Hepatology, 1999, 30, 546-549.	7.3	152
463	Melanoma-associated antigen recognized by T cells (MART-1). Cancer, 1999, 87, 37-42.	4.1	71
464	Expression in Transgenic Mice of Dominant Interfering Fas Mutations: A Model for Human Autoimmune Lymphoproliferative Syndrome. Clinical Immunology, 1999, 93, 34-45.	3.2	20
465	Resolution of chronic delta hepatitis after 12 years of interferon alfa therapy. Gastroenterology, 1999, 117, 1229-1233.	1.3	135
466	Melanomaâ€associated antigen recognized by T cells (MARTâ€1). Cancer, 1999, 87, 37-42.	4.1	5
467	Zymography, Casein Zymography, and Reverse Zymography: Activity Assays for Proteases and their Inhibitors. , 1999, , 63-76.		9
468	Long-Term Follow-Up of Chimpanzees Inoculated with the First Infectious Clone for Hepatitis C Virus. Journal of Virology, 1999, 73, 3317-3325.	3.4	137

#	Article	IF	CITATIONS
469	Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis. Clinical and Experimental Metastasis, 1998, 16, 217-225.	3.3	129
470	Pruritus as a presenting symptom of chronic hepatitis C. Digestive Diseases and Sciences, 1998, 43, 2177-2183.	2.3	63
471	10-year follow-up after interferon-? therapy for chronic hepatitis C. Hepatology, 1998, 28, 1121-1127.	7.3	275
472	Polypoid lesions of airways: early experience with computer-assisted detection by using virtual bronchoscopy and surface curvature Radiology, 1998, 208, 331-337.	7.3	71
473	Cushing's Syndrome Caused by Corticotropin Secretion by Pulmonary Tumorlets. New England Journal of Medicine, 1998, 339, 883-886.	27.0	52
474	Effect of inhibition of ornithine decarboxylase activity in a model of acute hepatocellular necrosis. European Journal of Gastroenterology and Hepatology, 1998, 10, 503-508.	1.6	1
475	Progelatinase A mRNA Expression in cell lines derived from tumors in patients with metastatic renal cell carcinoma correlates inversely with survival. Urology, 1997, 50, 295-301.	1.0	23
476	Perirenal myelolipoma. Urology, 1997, 49, 128-130.	1.0	24
477	Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology, 1997, 113, 1660-1667.	1.3	315
478	Quantitative Reverse Zymography: Analysis of Picogram Amounts of Metalloproteinase Inhibitors Using Gelatinase A and B Reverse Zymograms. Analytical Biochemistry, 1997, 244, 161-166.	2.4	160
479	Adrenocortical Neoplasms: Role of Prognostic Markers MIB-1, P53, and RB. American Journal of Surgical Pathology, 1997, 21, 556-562.	3.7	87
480	Histopathologic changes associated with fialuridine hepatotoxicity. Modern Pathology, 1997, 10, 192-9.	5.5	55
481	Assessment of monoethylglycinexylidide as measure of liver function for patients with chronic viral hepatitis. Clinical Chemistry, 1997, 43, 1952-7.	3.2	3
482	Molecular regulation of cellular invasion— role of gelatinase A and TIMP-2. Biochemistry and Cell Biology, 1996, 74, 823-831.	2.0	83
483	MMP-2: Expression, Activation and Inhibition. Enzyme & Protein, 1996, 49, 7-19.	1.4	183
484	Prolonged therapy of chronic hepatitis C with ribavirin. Journal of Viral Hepatitis, 1996, 3, 247-252.	2.0	63
485	Ribavirin as Therapy for Chronic Hepatitis C. Annals of Internal Medicine, 1995, 123, 897.	3.9	310
486	Expression of transforming growth factor alpha in the liver before and after interferon alfa therapy for chronic hepatitis B. Hepatology, 1995, 22, 1021-1026.	7.3	8

#	Article	IF	CITATIONS
487	Hepatic involvement in mastocytosis: Clinicopathologic correlations in 41 cases. Hepatology, 1995, 22, 1163-1170.	7.3	64
488	Increased Human Immunodeficiency Virus (HIV) Type 1 DNA Content and Quinolinic Acid Concentration in Brain Tissues from Patients with HIV Encephalopathy. Journal of Infectious Diseases, 1995, 172, 638-647.	4.0	55
489	Hepatic Failure and Lactic Acidosis Due to Fialuridine (FIAU), an Investigational Nucleoside Analogue for Chronic Hepatitis B. New England Journal of Medicine, 1995, 333, 1099-1105.	27.0	593
490	Volunteer Blood Donors with Antibody to Hepatitis C Virus: Clinical, Biochemical, Virologic, and Histologic Features. Annals of Internal Medicine, 1995, 123, 330.	3.9	239
491	Expression of transforming growth factor alpha in the liver before and after interferon alfa therapy for chronic hepatitis B*1. Hepatology, 1995, 22, 1021-1026.	7.3	12
492	Necropsy as a research method in the age of molecular pathology. Lancet, The, 1995, 346, 945-948.	13.7	44
493	Hepatic involvement in mastocytosis: Clinicopathologic correlations in 41 cases*1. Hepatology, 1995, 22, 1163-1170.	7.3	95
494	Regulation of Matrix Metalloproteinases during Extracellular Matrix Turnover. Advances in Experimental Medicine and Biology, 1995, 385, 151-159.	1.6	29
495	Quantitative Analysis of Viral Burden in Tissues from Adults and Children with Symptomatic Human Immunodeficiency Virus Type 1 Infection Assessed by Polymerase Chain Reaction. Journal of Infectious Diseases, 1994, 170, 325-333.	4.0	49
496	RB tumor suppressor gene expression in hepatocellular carcinomas from patients infected with the hepatitis B virus. Journal of Medical Virology, 1994, 44, 67-73.	5.0	31
497	Quantitative Zymography: Detection of Picogram Quantities of Gelatinases. Analytical Biochemistry, 1994, 218, 325-329.	2.4	810
498	Calectin-3 Is a Novel Substrate for Human Matrix Metalloproteinases-2 and -9. Biochemistry, 1994, 33, 14109-14114.	2.5	251
499	Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C. Journal of Hepatology, 1994, 21, 1109-1112.	3.7	65
500	Cellular activation of the 72 kDa type IV procollagenase/TIMP-2 complex. Kidney International, 1993, 43, 163-170.	5.2	120
501	Structural biochemistry and activation of matrix metalloproteases. Current Opinion in Cell Biology, 1993, 5, 891-897.	5.4	335
502	Stability analysis of latent and active 72-kDa type IV collagenase: The role of tissue inhibitor of metalloproteinases-2 (TIMP-2). Biochemistry, 1993, 32, 1583-1592.	2.5	80
503	Fazarabine. American Journal of Clinical Oncology: Cancer Clinical Trials, 1993, 16, 34-37.	1.3	2
504	Extracellular matrix 6: Role of matrix metalloproteinases in tumor invasion and metastasis. FASEB Journal, 1993, 7, 1434-1441.	0.5	554

#	Article	IF	CITATIONS
505	Mutations of p53 Gene in Hepatocellular Carcinoma: Roles of Hepatitis B Virus and Aflatoxin Contamination in the Diet. Journal of the National Cancer Institute, 1992, 84, 1638-1641.	6.3	61
506	Higher-order complex formation between the 72-kilodalton type IV collagenase and tissue inhibitor of metalloproteinases-2. Biochemistry, 1992, 31, 1665-1672.	2.5	63
507	Unusual aspects of allergic bronchopulmonary fungal disease: Report of two cases due to Curularia organisms associated with allergic fungal sinusitis. Human Pathology, 1991, 22, 1240-1248.	2.0	85
508	Primary sarcoma of the heart causing mitral stenosis. American Journal of Cardiology, 1990, 66, 893-895.	1.6	12
509	Digital Necrosis and Disseminated Pneumocystis carinii Infection after Aerosolized Pentamidine Prophylaxis. Annals of Internal Medicine, 1989, 111, 681.	3.9	71
510	The effect of a phase transition on penetration of phospholipid monolayers by melittin and glucagon. Archives of Biochemistry and Biophysics, 1983, 227, 242-247.	3.0	13